These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 37060398)

  • 1. Nanomedicines: intervention in inflammatory pathways of cancer.
    Anwar F; Naqvi S; Shams S; Sheikh RA; Al-Abbasi FA; Asseri AH; Baig MR; Kumar V
    Inflammopharmacology; 2023 Jun; 31(3):1199-1221. PubMed ID: 37060398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced nanomedicines for the treatment of inflammatory diseases.
    Brusini R; Varna M; Couvreur P
    Adv Drug Deliv Rev; 2020; 157():161-178. PubMed ID: 32697950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor microenvironment and nanotherapeutics: intruding the tumor fort.
    Ravi Kiran AVVV; Kusuma Kumari G; Krishnamurthy PT; Khaydarov RR
    Biomater Sci; 2021 Nov; 9(23):7667-7704. PubMed ID: 34673853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.
    Bertrand N; Wu J; Xu X; Kamaly N; Farokhzad OC
    Adv Drug Deliv Rev; 2014 Feb; 66():2-25. PubMed ID: 24270007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The development of novel tumor targeting delivery strategy].
    Gao HL; Jiang XG
    Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating the tumor microenvironment with new therapeutic nanoparticles: A promising paradigm for tumor treatment.
    Zhang Y; Ho SH; Li B; Nie G; Li S
    Med Res Rev; 2020 May; 40(3):1084-1102. PubMed ID: 31709590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms.
    Zi Y; Yang K; He J; Wu Z; Liu J; Zhang W
    Adv Drug Deliv Rev; 2022 Sep; 188():114449. PubMed ID: 35835353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to improve the EPR effect: A mechanistic perspective and clinical translation.
    Ikeda-Imafuku M; Wang LL; Rodrigues D; Shaha S; Zhao Z; Mitragotri S
    J Control Release; 2022 May; 345():512-536. PubMed ID: 35337939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
    Danhier F; Feron O; Préat V
    J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
    Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
    Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological rationale for the design of polymeric anti-cancer nanomedicines.
    Zhou Y; Kopeček J
    J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcytosis-enabled active extravasation of tumor nanomedicine.
    Zhou Q; Li J; Xiang J; Shao S; Zhou Z; Tang J; Shen Y
    Adv Drug Deliv Rev; 2022 Oct; 189():114480. PubMed ID: 35952830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Abnormality-Oriented Nanomedicine Design.
    Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
    Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites.
    Dong X; Chu D; Wang Z
    Theranostics; 2017; 7(3):751-763. PubMed ID: 28255364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.
    Fakhri S; Moradi SZ; Faraji F; Farhadi T; Hesami O; Iranpanah A; Webber K; Bishayee A
    Cancer Metastasis Rev; 2023 Sep; 42(3):959-1020. PubMed ID: 37505336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
    Kwon S; Ko H; You DG; Kataoka K; Park JH
    Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.